International Multi-center Open-label Randomized Clinical Trial of Efficacy, Safety and Pharmacokinetics of BCD-100 (JSC "BIOCAD", Russia) Monotherapy Compared to Docetaxel as Second-line Therapy of Patients With Advanced Inoperable or Metastatic Non-small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs Adalimumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms DOMINUS
- Sponsors Biocad
- 10 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 05 Mar 2018 Status changed from not yet recruiting to recruiting.
- 22 Sep 2017 New trial record